Therapeutic Arthritis Research & Gastrointestinal Event Trial (TARGET)

Introduction

Study characteristics:

18,325 patients > 50 years of age with osteoarthritis

Patients ramdomized to treatment group for 52 weeks:

• lumiracoxib 400 mg QD
• naproxen 500 mg BID
• ibuprofen 800 mg TID

Results:

• among patients who did not take 81 mg aspirin,the lumiracoxib group had significantly fewer peptic ulcer complications
• no signficant difference in peptic ulcer complications was found in patients taking 81 mg of aspirin
• elevated serum transaminases noted in the lumiracoxib group

More general terms

• clinical trial

Additional terms

• abdominal pain